JANX - NASDAQ
Janux Therapeutics, Inc.
$13.59
-1.4%Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
At a Glance
Live SnapshotJanux Therapeutics, Inc. Management Team
Mr. Andy Hollman Meyer
Chief Business Officer
Dr. Zachariah McIver D.O., Ph.D.
Chief Medical Officer
Dr. Thomas Diraimondo Ph.D.
Chief Scientific Officer
Compensation
$630,000
Mr. Byron Robinson J.D., Ph.D.
Chief Strategy Officer
Compensation
$727,500
Mr. Charles M. Winter
Chief Technical Officer
Compensation
$590,400
Mr. James Pennington
General Counsel & Corporate Secretary
Dr. David Alan Campbell Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,130,500
Ms. Maria Dobek
Principal Accounting Officer & Vice President of Accounting
Mr. Matt Whitmire
Vice President of Finance
Janux Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $549K worth of JANX shares, with no buying activity reported.
3 Months
0
0.00
2.0K
28.88K
-29K
-$29K
3-6 Months
0
0.00
19.0K
261.32K
-261K
-$261K
6-9 Months
0
0.00
12.7K
259.29K
-259K
-$259K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Meyer Andrew Hollman
Officer: Chief Business Officer
$285K
Campbell David Alan
Director, Officer: President And Ceo
$111K
Dobek Maria
Officer: Vice President, Accounting
$49K
Mciver Zachariah
Officer: Chief Medical Officer
$37K
Diraimondo Thomas
Officer: Chief Scientific Officer
$34K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $549K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
JANX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | April 25, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 26, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 14, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 14, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.